TrialEuropean journal of immunology2016

Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.

James E Tooley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.